Skip to main content

Advertisement

Table 4 Quantitation of tumor and liver uptake of 86Y-CHX-A"-panitumumab F(ab')2 by PET imaging.

From: In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

    Time post-injection (h)
Protein dose Blocked Organ 24 48
3 μg No Tumor 20.31 ± 1.52a 22.59 ± 1.51
   Liver 12.98 ± 0.95 11.68 ± 0.43
  Yes Tumor 11.37 ± 0.58 9.92 ± 0.66
   Liver 12.34 ± 0.99 12.95 ± 0.88
15 μg No Tumor 20.30 ± 1.01 22.98 ± 0.84
   Liver 13.84 ± 0.5 11.62 ± 1.12
  Yes Tumor 11.44 ± 0.69 11.38 ± 0.96
   Liver 12.60 ± 0.70 10.66 ± 0.57
  1. The values presented are the percentage of injected dose per cubic centimeter. Receptor-mediated uptake of 86Y-CHX-A"-panitumumab F(ab')2 of LS-174T tumor xenografts and normal organs 2 days post-injection of the RIC. Data represent the mean ± SEM from at least three determinations. The specific activity of the 86Y- CHX-A"-panitumumab F(ab')2 was lowered by the addition of 15 μg of panitumumab F(ab')2.